An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
There has been no effective treatment for advanced thyroid cancer that is not amenable to
surgery and that does not concentrate iodine. Response rates with chemotherapy have been so
low that best supportive care has been the standard of care for most patients. In recent
phase I and phase II clinical studies, dovitinib has shown activity as a single agent in
solid tumors. Therefore, we will conduct a phase II, single-arm trial to determine the
efficacy of dovitinib in radioactive iodine-refractory recurrent or metastatic thyroid
cancer.